Agios hit a setback for Tibsovo in Europe this year however after the EMA rejected the marketing application for the drug. Servier is paying $1.8 billion upfront for the oncology assets ...
Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma's oncology business after getting a key FDA approval for Tibsovo, the main asset in the deal. The US regulator has ...
Hosted on MSN8mon
Alembic Pharma gets tentative nod from USFDA for Ivosidenib tabletsThe approved ANDA is therapeutically equivalent to the reference listed drug product Tibsovo tablets, 250 mg, of Servier Pharmaceuticals LLC (Servier), it added. The company said Ivosidenib ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback